Abstract: The present disclosure provides compositions and methods for treating a disease, such as cancer or a tumor, comprising: administering successive doses of an anti-PD-1 antibody composition comprising an anti-PD-1 antibody, or antigen binding fragment thereof, such as pembrolizumab or a pembrolizumab variant to the subject and administering successive doses of a decoy-resistant (DR) IL-18 composition comprising a DR IL-18 polypeptide to the subject; thereby improving the condition of the subject, such as e.g., causing immunotherapy-induced regression of the disease in the subject, such as immunotherapy-induced regression of a cancer or tumor.

Abstract: The present disclosure provides compositions and methods comprising stabilized IL-18 polypeptides for use in therapeutic and non-therapeutic applications. In some cases, the stabilized IL-18 proteins provide IL-18 signaling activity even in the presence of an inhibitory molecule such as IL-18BP. Also provide are methods of administration and methods for making active polypeptides.

Abstract: The present disclosure provides compositions and methods comprising stabilized IL-18 polypeptides for use in therapeutic and non-therapeutic applications. In some cases, the stabilized IL-18 proteins provide IL-18 signaling activity even in the presence of an inhibitory molecule such as IL-18BP. Also provide are methods of administration and methods for making active polypeptides.

Abstract: The present disclosure provides compositions and methods comprising stabilized IL-18 polypeptides for use in therapeutic and non-therapeutic applications. In some cases, the stabilized IL-18 proteins provide IL-18 signaling activity even in the presence of an inhibitory molecule such as IL-18BP. Also provide are methods of administration and methods for making active polypeptides.